Merck KGaA has acquired the outstanding shares of common stock of Millipore Corporation for $107 per share in cash or a total transaction of $7.2 billion.
This deal will create a world class partner for the Life Science sector, with a comprehensive product offering and enhanced global scale and innovative power.
Together, Millipore and Merck will have a significant presence in high-growth segments and an enhanced geographic presence. Combining the research and development capabilities of both companies will create a powerful innovation platform to develop cutting-edge technologies that are tailored even more closely to the needs of customers.
Together the new EMD Millipore division will bring together complementary research and development capabilities to capture the significant opportunities in the high-growth, high-margin market segments such as bio-research and bio-production. The combination will enable Roche KGaA and Millipore to gain new insights and drive innovation.
EMD Millipore will have enhanced global manufacturing and distribution capabilities, which will allow it to compete more effectively in the marketplace. Additionally, a larger sales organization will lead to greater customer service and broader global sales coverage, opening up new growth opportunities.
EMD Millipore will consist of three business units – Bioscience, Lab Solutions and Process Solutions – and each unit will itself comprise a number of key focus areas, known as business fields.